These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22846497)

  • 1. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.
    Toubi E; Nussbaum S; Staun-Ram E; Snir A; Melamed D; Hayardeny L; Miller A
    J Neuroimmunol; 2012 Oct; 251(1-2):45-54. PubMed ID: 22846497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
    Lund BT; Kelland EE; Hayardeny L; Barilan O; Gilmore W; Weiner LP
    J Neuroimmunol; 2013 Oct; 263(1-2):108-15. PubMed ID: 23920036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
    Aharoni R; Saada R; Eilam R; Hayardeny L; Sela M; Arnon R
    J Neuroimmunol; 2012 Oct; 251(1-2):14-24. PubMed ID: 22749337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
    Ahn JS; Krishnadas DK; Agrawal B
    Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors.
    Reske D; Thomas AV; Petereit HF; Fink GR; Schroeter M
    Neuroimmunomodulation; 2009; 16(6):385-91. PubMed ID: 19609087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral laquinimod treatment in multiple sclerosis.
    Fernández O
    Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A defect of CD4+CD25+ regulatory T cells in inducing interleukin-10 production from CD4+ T cells under CD46 costimulation in asthma patients.
    Xu YQ; Gao YD; Yang J; Guo W
    J Asthma; 2010 May; 47(4):367-73. PubMed ID: 20528588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
    Bar-Or A; Fawaz L; Fan B; Darlington PJ; Rieger A; Ghorayeb C; Calabresi PA; Waubant E; Hauser SL; Zhang J; Smith CH
    Ann Neurol; 2010 Apr; 67(4):452-61. PubMed ID: 20437580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
    Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U
    Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
    Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
    Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
    Zilkha-Falb R; Gurevich M; Hayardeny L; Achiron A
    J Neuroimmunol; 2015 Jun; 283():11-6. PubMed ID: 26004150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis.
    Mokhtarian F; Shi Y; Shirazian D; Morgante L; Miller A; Grob D
    J Immunol; 1994 Jun; 152(12):6003-10. PubMed ID: 8207225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive effects of rat mesenchymal stem cells: involvement of CD4+CD25+ regulatory T cells.
    Ye Z; Wang Y; Xie HY; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2008 Dec; 7(6):608-14. PubMed ID: 19073406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The T cell response to major grass allergens is regulated and includes IL-10 production in atopic but not in non-atopic subjects.
    Domdey A; Liu A; Millner A; Lund K; Jacobi H; Malling HJ; Søndergaard I; Würtzen PA
    Int Arch Allergy Immunol; 2010; 152(3):243-54. PubMed ID: 20150742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells.
    Dumitriu IE; Dunbar DR; Howie SE; Sethi T; Gregory CD
    J Immunol; 2009 Mar; 182(5):2795-807. PubMed ID: 19234174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor beta-producing Foxp3(+)CD8(+)CD25(+) T cells induced by iris pigment epithelial cells display regulatory phenotype and acquire regulatory functions.
    Sugita S; Futagami Y; Horie S; Mochizuki M
    Exp Eye Res; 2007 Nov; 85(5):626-36. PubMed ID: 17720157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The suppressive effect of CD25+Treg cells on Th1 differentiation requires cell-cell contact partially via TGF-β production.
    Shen E; Zhao K; Wu C; Yang B
    Cell Biol Int; 2011 Jul; 35(7):705-12. PubMed ID: 21314640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.